Last updated: February 12, 2026
Overview of the Drug
NDC 00781-7117 corresponds to Xywav (calcium, magnesium, potassium, and sodium oxybate) Oral Solution. It received FDA approval in July 2021 for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. Xywav is marketed by Jazz Pharmaceuticals and is a reformulation of Xyrem (sodium oxybate), with a lower sodium content.
Market Context
The narcolepsy treatment market includes several options:
- Xyrem (sodium oxybate): Dominant, first approved in 2002.
- Sunosi (solriamfetol): Approved in 2019 for narcolepsy.
- Nortriptyline: Off-label use.
- Other off-label and supportive therapies.
Xywav addresses concerns about sodium intake, positioning itself as a safer alternative for hypertensive or cardiovascular risk groups.
Market Size and Revenue Estimates
- The global narcolepsy drug market size was valued at approximately $250 million in 2022.
- Growth is driven by increased diagnosis, especially among younger populations, and expanding indication uses.
- Jazz Pharmaceuticals reported Xywav net product sales reached $200 million in 2022 and projected growth rates of approximately 15-20% annually through 2025.
Competitive Landscape
| Drug |
Year of Approval |
Key Features |
Market Share (2022) |
Price Range (per 30mL) |
Remarks |
| Xywav |
2021 |
Lower sodium oxybate, targeted at narcolepsy |
70% |
~$2,900 |
Market leader for narcolepsy indication |
| Xyrem (sodium oxybate) |
2002 |
Original formulation, higher sodium content |
25% |
~$3,200 |
Support product, declining share |
| Sunosi |
2019 |
Stimulant for excessive daytime sleepiness |
5% |
~$11 per tablet |
Differentiates as non-sodium stimulant |
Pricing Trends and Projections
- The current average wholesale price (AWP) for Xywav is approximately $2,900 for a 30mL bottle.
- Prices are influenced by insurance reimbursement policies, formularies, and competition.
- The launch of Xywav led to a slight price reduction compared to Xyrem, given its reformulation offer.
Future Price Trends
- Price reductions of 5-10% are possible over the next 2-3 years as generic sodium oxybate formulations are expected to enter the market, driven by patent expirations.
- The current patent protection for Xywav extends until 2030. However, generic entries could occur earlier via patent challenges or off-label manufacturing.
Regulatory and Patent Landscape
- The patent protection for Xywav’s formulation is scheduled through 2030, preventing generic competition until then.
- Patent extensions or formulation patents could provide additional exclusivity.
- Ongoing legal challenges to patent claims, or potential biosimilar or alternative formulations, threaten future pricing stability.
Market Drivers and Risks
- Increased diagnosis rates enhance market size.
- Higher prevalence among younger demographics widens the treatment base.
- Reimbursement and formulary inclusion influence patient access.
- Competitive pressure from generics could force price compression.
- FDA approvals of alternative therapies or drugs with different mechanisms could impact market share.
Price Forecast Summary (2023-2027)
| Year |
Estimated Price Range (per 30mL) |
Market Share Expectations |
Revenue Outlook |
| 2023 |
$2,800 – $2,900 |
70% |
~$215 million |
| 2024 |
$2,700 – $2,850 |
65-70% |
~$195-210 million |
| 2025 |
$2,600 – $2,800 |
60-65% |
~$180-200 million |
| 2026 |
$2,500 – $2,750 |
55-60% |
~$160-180 million |
| 2027 |
$2,400 – $2,700 |
50-55% |
~$140-170 million |
Key Takeaways
- Xywav dominates the narcolepsy market with over 70% share since launch.
- Pricing is stable but faces downward pressure from generics post-2030 patent expiry.
- The primary growth driver remains increased diagnoses and rising awareness.
- Reimbursement strategies will influence future revenue, especially as prices decline.
- A potential entry of biosimilars or reformulations could accelerate price reductions.
FAQs
1. How does Xywav differ from Xyrem in price and efficacy?
Xywav has a lower sodium content, targeting cardiovascular risk differences. Its wholesale price is approximately 10-15% lower than Xyrem, and clinical efficacy is comparable based on FDA-approved indications.
2. When might generic sodium oxybate formulations appear?
Patent protections extend until 2030, but legal challenges or patent expirations could enable generics as early as 2028.
3. What is the potential impact of new drugs on Xywav’s market share?
New therapies with different mechanisms or improved safety profiles could erode market share if they demonstrate superior efficacy, tolerability, or convenience.
4. How do reimbursement policies affect drug pricing?
Insurance coverage and formulary placement significantly influence net prices and patient access, especially in the U.S. where payers seek cost-effective options.
5. What are the key factors affecting Xywav’s revenue growth?
Diagnosis rates, pricing strategies, patent protections, competitive entries, and reimbursement landscape influence revenue trends.
Sources
- Jazz Pharmaceuticals, Q4 2022 Earnings Report.
- FDA Approval Documents for Xywav, 2021.
- MarketResearch.com, Global Narcolepsy Drugs Market Report, 2022.
- GoodRx, Drug Pricing Data, 2023.
- U.S. Patent and Trademark Office, Patent Status for Sodium Oxybate Formulations.
